Beyond Air shares plunge 21.01% intraday following $5.0M private placement and NeuroNOS subsidiary stake sale to XTL Biopharma.

Beyond Air (XAIR) plunged 21.01% intraday following the announcement of a $5.0 million private placement priced at-the-market under Nasdaq rules. The transaction involves issuing 3.93 million shares and warrants, with proceeds intended for working capital and general corporate purposes. The dilutive nature of the offering, combined with the issuance of warrants exercisable at $1.147 per share, likely triggered investor concerns over equity dilution and potential downward pressure on the stock price. While the company’s prior partnership with XTL Biopharmaceuticals (acquiring its NeuroNOS subsidiary) had initially driven a surge in XAIR, the subsequent capital raise appears to have overshadowed earlier optimism, leading to the sharp intraday decline.